Company Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology.
The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients.
Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Mar 24, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Gabriele Marco Antonio Cerrone M.B.A. |
Contact Details
Address: 3rd Floor, 11-12 St. James's Square London, England, X0 SW1Y 4LB United Kingdom | |
| Phone | 0044(0) 207-495-2379 |
| Website | tizianalifesciences.com |
Stock Details
| Ticker Symbol | TLSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001723069 |
| CUSIP Number | 88875G101 |
| ISIN Number | BMG889121031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gabriele Marco Antonio Cerrone M.B.A. | Founder, Executive Chairman and Interim Chief Executive Officer |
| Dr. Andrea Brancale | Scientific Founder |
| Richard Clarkson Ph.D. | Scientific Founder |
| Andrew Westwell Ph.D. | Scientific Founder |
| Keeren Shah | Chief Financial Officer |
| Dr. Matthew W. Davis M.D., R.Ph. | Chief Operating Officer and Chief Medical Officer |
| Dr. William A. Clementi Ph.D., Pharm.D. | Chief Development Officer |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 23, 2024 | 6-K | Report of foreign issuer |
| Apr 22, 2024 | 6-K | Report of foreign issuer |
| Apr 19, 2024 | 6-K | Report of foreign issuer |
| Apr 18, 2024 | 6-K | Report of foreign issuer |
| Apr 11, 2024 | 6-K | Report of foreign issuer |
| Mar 5, 2024 | 6-K | Report of foreign issuer |
| Jan 8, 2024 | 6-K | Report of foreign issuer |
| Jan 5, 2024 | 6-K | Report of foreign issuer |
| Jan 5, 2024 | 6-K | Report of foreign issuer |